The CaM inhibitor hydrazinobenzoylcurcumin has anti-tumor effects by inhibiting, among other processes, the migratory and the invasive capacity of glioblastoma stem cells as a result of targeting the CaMK-II/c-Ret pathway [239]. This evidence concerns the gene CALM3 and neoplasm.